Thera-SAbDab

MARGETUXIMAB

>   Structural Summary
TherapeuticMargetuximab
TargetERBB2
Heavy ChainQVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSS
Light ChainDIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAWYQQKPGHSPKLLIYSASFRYTGVPDRFTGSRSGTDFTFTISSVQAEDLAVYYCQQHYTTPPTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2013
INN Year Recommended2014
Companies InvolvedRaven biotechnologies, GC Pharma, Green Cross, MacroGenics, Merck Sharp & Dohme
Conditions Approvedna
Conditions ActiveBreast cancer, Gastric cancer
Conditions DiscontinuedBladder cancer, Non-small cell lung cancer, Ovarian cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]